US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00%
FinancialContent

Articles published by atai Life Sciences

< Previous 1 2 Next >
News headline image
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Pricing of Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Proposed Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Awarded Grant from the National Institutes of Health
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences to Participate in September Investor Conferences
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces $50 Million Private Placement Financing
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences to Participate in Upcoming Investor Conferences
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Pricing of Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Proposed Public Offering of Common Shares
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
News headline image
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
From atai Life Sciences
Via GlobeNewswire
Tickers ATAI
< Previous 1 2 Next >